Cosmos Health (Cosmos Health) Cash, Cash Equivalents, Marketable Securities : $2.38 Mil (As of Sep. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Cosmos Health Cash, Cash Equivalents, Marketable Securities?

Cosmos Health's quarterly cash, cash equivalents, marketable securities declined from Mar. 2023 ($12.05 Mil) to Jun. 2023 ($2.25 Mil) but then increased from Jun. 2023 ($2.25 Mil) to Sep. 2023 ($2.38 Mil).

Cosmos Health's annual cash, cash equivalents, marketable securities declined from Dec. 2020 ($0.85 Mil) to Dec. 2021 ($0.30 Mil) but then increased from Dec. 2021 ($0.30 Mil) to Dec. 2022 ($20.77 Mil).

Cosmos Health Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Cosmos Health's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmos Health Cash, Cash Equivalents, Marketable Securities Chart

Cosmos Health Annual Data

Trend

Jul13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

3.58

0.28

0.85

0.30

20.77

Cosmos Health Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															0.32	20.77	12.05	2.25	2.38

Cosmos Health Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Cosmos Health (NAS:COSM) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Cosmos Health Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Cosmos Health's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmos Health (Cosmos Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cosmos Health Inc (NAS:COSM) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

V67A:Germany

Address

141 West Jackson Boulevard, Suite 4236, Chicago, IL, USA, 60604

Website

https://www.cosmoshold.com

Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers.

Executives

Grigorios Siokas	10 percent owner	5 AG. GEORGIOU STR., PILEA, THESSALONIKI J3 TK57001
Suhel Bhutawala	director	141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Nikolaos Bardakis	officer: Chief Operating Officer	141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Manfred Ziegler	director	141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Anastasios Aslidis	director	11 CANTERBURY LANE, WATCHUNG NJ 07069
Pavlos Ignatiades	officer: Chief Operating Officer	KALAPATHAKI 5, PANORAMA, THESSALONIKI J3 55236
Georgios Terzis	officer: Chief Financial Officer	2 MELITOS STR., NEA SMIRNI, ATTICA J3 17121
Peter Goldstein	director	151 NORTH NOB HILL ROAD SUITE 321, FORT LAUDERDALE FL 33324
John James Hoidas	director	9301 S. HARLEM AVENUE, OAK LAWN, CHICAGO IL 60453
Dimitrios Goulielmos	director, 10 percent owner, officer: CEO	141 WEST JACKSON BLVD, SUITE 4236, CHICAGO IL 60604
Panagiotis Tolis	director, officer: Secretary	PERICLEOUS 50 STREET, ATHENS J3 15232
Panagiotis Drakopoulos	director, 10 percent owner, officer: CEO	200 SOUTH WACKER DRIVE, SUITE 300, CHICAGO IL 60606
Vasileios Mavrogiannis	director, 10 percent owner, officer: CFO	TERTSETI 23 STREET, KESARIANI J3 16122